paclitaxel has been researched along with Adenocarcinoma, Clear Cell in 134 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (5.97) | 18.2507 |
| 2000's | 44 (32.84) | 29.6817 |
| 2010's | 76 (56.72) | 24.3611 |
| 2020's | 6 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WH; Lai, WA; Lee, NR; Lee, WL; Shen, SH; Wang, PH; Yang, ST | 1 |
| Chang, CL; Chang, HT; Chen, JR; Chen, TC; Chiu, ML; Su, TH; Wang, KG; Wang, KL; Wang, TY; Yang, YC | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Areepium, N; Liblab, S; Vusuratana, A | 1 |
| Lam, LL; Levingston, R; O'Neill, RS; Solanki, P; Thomas, D | 1 |
| Aoki, D; Enomoto, T; Fujiwara, K; Kimura, E; Kondo, E; Kotera, Y; Okamoto, A; Sugiyama, T; Sumi, T; Suzuki, N; Tabata, T; Terauchi, F; Tokuyama, O; Yaegashi, N; Yahata, H | 1 |
| Broadwater, G; Chino, JP; Foote, J; Gaillard, S; Havrilesky, LJ; Hong, JC | 1 |
| Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A | 1 |
| Bassiouny, D; Bernardini, MQ; Brar, H; Covens, A; Ferguson, SE; Gien, LT; Hogen, L; Vicus, D | 1 |
| Chiba, Y; Fukagawa, D; Itamochi, H; Kawamura, H; Kojima-Chiba, A; Muraki, Y; Sato, S; Suga, Y; Sugai, T; Sugiyama, T; Yoshino, N | 1 |
| Argenta, PA; Armstrong, DK; Birrer, M; Bookman, MA; Brady, WE; Burger, RA; Copeland, LJ; Farley, JH; Fleming, G; Gershenson, DM; Mannel, RS; Muggia, FM; Mutch, DG; Oliver, KE; Rose, PG; Secord, AA; Stehman, FB; Stephan, JM; Tewari, K | 1 |
| Asher, R; Beale, P; Friedlander, M; Kwok, JB; Lee, CK; Park, SB; Selle, F | 1 |
| Ayhan, A; Celik, H; Coban, G; Cuylan, ZF; Güngör, T; Haberal, AN; Meydanli, MM; Sahin, H; Sari, ME; Sirvan, L; Yalcin, I | 1 |
| de Melo, AC; de Moraes Lino da Silva, F; Fontes Dias, MS; Ingles Garces, ÁH; Moreira, E; Paulino, E; Saramago, M; Thuler, LCS | 1 |
| Gordon, AN; Horowitz, IR; Khanna, N; Lachiewicz, MP | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Ishikura, N; Kurasawa, M; Sugimoto, M; Yamamoto, K; Yanagisawa, M; Yorozu, K | 1 |
| Armstrong, DK; Birrer, MJ; Darcy, KM; Deloia, JA; Krivak, TC; Lesnock, JL; Thrall, MM; Tian, C; Zahn, C | 1 |
| Ayeni, TA; Bakkum-Gamez, JN; Dowdy, SC; Haddock, MG; Keeney, GL; Long, HJ; Mariani, A; McGree, ME; Podratz, KC; Weaver, AL | 1 |
| Aghajanian, CA; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q | 1 |
| Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Kamura, T; Muto, M; Nishio, S; Ota, S; Sonoda, G; Takemoto, S; Ushijima, K | 1 |
| Chalapati, W; Suprasert, P | 1 |
| Bookman, MA; Gatcliffe, TA; Java, JJ; Monk, BJ; Tewari, KS | 1 |
| Ditto, A; Lorusso, D; Mancini, M; Ramondino, S; Raspagliesi, F; Zanaboni, F | 1 |
| Baranowski, W; Bodnar, L; Cichowicz, M; Cierniak, S; Dąbek, A; Gąsowska-Bodnar, A; Jerzak, M; Kozłowski, W | 1 |
| Chang, CL; Chen, CP; Cheng, JT; Lee, WL; Seow, KM; Tsui, KH; Wang, PH; Wang, SY; Yang, LW; Yen, MS | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Habata, S; Iwasaki, M; Mariya, T; Osogami, H; Saito, T; Sugio, A; Suzuki, M; Tamate, M; Tanaka, R | 1 |
| Morikawa, A; Nagata, C; Okamoto, A; Saito, M; Suzuki, J; Suzuki, K; Takahashi, K; Takakura, S; Tanabe, H; Yanaihara, N | 1 |
| Akman, T; Ellidokuz, H; Unal, OU; Yavuzsen, T; Yilmaz, AU | 1 |
| Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Abe, A; Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sueoka, K; Takeshima, N; Umayahara, K; Usami, T; Yamamoto, A | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Aziz, AB; Chishti, U | 1 |
| Chu, C; Lin, LL; Rubin, S; Xu, MJ | 1 |
| Chang, SF; Cheng, WF; Ho, CM; Huang, CJ; Huang, SH | 1 |
| Elbassuiony, MA; Elsayed, AM; Helal, AM; Ismail, YM; Moneer, MM; Nassar, HR; Zeeneldin, AA | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Chiba, Y; Chikumi, J; Harada, T; Itamochi, H; Komatsu, H; Kudoh, A; Nonaka, M; Oishi, T; Oumi, N; Sato, S; Shimada, M; Sugiyama, T | 1 |
| Hashimoto, K; Kawano, M; Kimura, T; Kozasa, K; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, R | 1 |
| Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Cirik, DA; Karalok, A; Koc, S; Tasci, T; Tulunay, G; Turan, T; Ureyen, I | 1 |
| Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW | 1 |
| Alexandre, J; Aoki, D; Aotani, E; Enomoto, T; Fujiwara, K; Green, J; Hamano, T; Isonishi, S; Kato, K; Kim, BG; Kim, JW; Mikami, M; Nishino, K; Nomura, H; Okamoto, A; Pignata, S; Sugiyama, T; Suzuki, N; Tanabe, H; Terao, Y; Terauchi, F; Yaegashi, N; Yokoyama, Y; Yoshikawa, H | 1 |
| Ahn, KJ; An, IS; An, S; Bae, S; Choi, YM; Kim, TJ; Lee, J; Lee, JH | 1 |
| Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL | 1 |
| Bai, H; Cao, D; Chen, J; Sha, G; Shen, K; Wang, Y; Yang, J; Yuan, F; Zhang, Z | 1 |
| Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R | 1 |
| Fujimura, Y; Iwata, M; Kato, K; Maeda, K; Moriyama, T; Ohsawa, I; Sakamoto, T; Sanda, T; Tabata, M | 1 |
| Chen, Q; Lin, ZQ; Tan, YT; Wang, LJ; Zhang, BZ; Zhang, X | 1 |
| Konishi, I; Sugiyama, T | 1 |
| Sawada, M; Uehara, T | 1 |
| Aoki, D; Basaki, Y; Hattori, S; Kono, S; Kuwano, M; Oda, Y; Ohishi, Y; Oie, S; Ono, M; Suzuki, N; Taguchi, K; Tsuneyoshi, M; Yanagawa, T | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, YM; Kim, YS; Kim, YT; Lee, SW; Nam, JH; Shin, SS | 1 |
| Altaras, M; Ben-Harim, Z; Bruchim, I; Fishman, A; Shechter-Maor, G | 1 |
| Agheli, A; Huang, CJ; Park, SC; Wang, JC | 1 |
| Amant, F; Berteloot, P; Capoen, A; Leunen, K; Moerman, P; Neven, P; Van Calster, B; Vandenput, I; Vergote, I | 1 |
| Jakobsen, A; Steffensen, KD; Waldstrøm, M | 1 |
| Chew, I; Park, KJ; Soslow, RA | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Senga, T; Shibata, K; Shimaoka, M; Umezu, T; Yamamoto, E | 1 |
| Abe, K; Ishiko, O; Sumi, T; Yoshida, H | 1 |
| Bell, J; Chan, JK; Fleming, GF; Herzog, TJ; Kapp, DS; Monk, BJ; Tian, C | 1 |
| Bamias, A; Bournakis, E; Dimopoulos, MA; Haidopoulos, D; Lianos, E; Papadimitriou, C; Psaltopoulou, T; Rodolakis, A; Sotiropoulou, M; Vlahos, G | 1 |
| Aletti, GD; Cliby, WA; Gallenberg, M; Hartmann, L; Long, HJ; Nordquist, D | 1 |
| Aoki, D; Inaba, N; Noda, K; Ochiai, K; Saito, T; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M | 1 |
| Khunamornpong, S; Sirichaisutdhikorn, D; Suprasert, P | 1 |
| Liu, XS; Shao, SL | 1 |
| Chen, YJ; Chen, YY; Lai, JC; Lin, CP; Tsai, TH; Wang, KL; Wang, SC; Wu, YT; Yang, YC | 1 |
| Chen, TC; Cheng, WF; Chien, CC; Ho, CM; Hsieh, CY; Huang, SH; Lin, MC; Liu, FS; Wang, TY; Yu, MH | 1 |
| Goto, T; Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Tsuda, H; Udagawa, Y; Yaegashi, N | 1 |
| Hassall, T; Nicklin, J; Singh, P | 1 |
| Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Hirano, M; Kataoka, H; Kiriyama, T; Kitauchi, T; Saito, K; Ueno, S | 1 |
| Hwang, JH; Lee, JK; Lee, KW; Lee, NW; Shin, BK; Song, SH | 1 |
| Gregoriou, O; Grigoriadis, C; Iavazzo, C; Kondi-Pafiti, A; Papakonstantinou, E; Salakos, N | 1 |
| Chen, X; Li, H; Li, K; Li, X; Liu, Y; Lou, G; Yin, M; Zhang, H | 1 |
| Dogan, A; Ertas, IE; Gultekin, E; Gultekin, OE; Yildirim, Y | 1 |
| Ino, K; Kajiyama, H; Kawai, M; Kikkawa, F; Nagasaka, T; Nawa, A; Shibata, K; Suzuki, S | 1 |
| Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P | 1 |
| Amant, F; Neven, P; Vandenput, I; Vergote, I | 1 |
| Chang, SF; Cheng, WF; Ho, CM; Huang, CJ; Huang, CY; Wu, YY | 1 |
| Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R | 1 |
| Li, M; Mao, N; Pan, L; Yin, J | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N | 1 |
| Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H | 1 |
| Davis, R; Lance, R; Peterson, AC | 1 |
| Chien, TY; Ho, CM; Huang, SH; Shih, BY | 1 |
| Date, K; Egawa, M; Fujitoh, N; Fujiwara, H; Furukawa, M; Mizunoe, T; Sakashita, T; Ueda, K; Urabe, S; Urabe, T | 1 |
| Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A | 1 |
| Chang Chien, CC; Chen, TC; Ho, CM; Hsieh, CY; Huang, SH; Huang, YJ; Liu, FS; Mao, TL; Wang, TY; Yu, MH | 1 |
| Atabekoglu, C; Berker, B; Bilgin, T; Dunder, I | 1 |
| Akizuki, S; Andoh, M; Fujiwara, Y; Katsumata, N; Watanabe, T; Yamanaka, Y | 1 |
| Bamias, A; Bozas, GT; Dimopoulos, MA; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Vlahos, G | 1 |
| Aki, T; Asada, M; Enomoto, T; Ikegami, H; Ito, K; Kameda, T; Kuragaki, C; Mizutani, T; Murata, Y; Nagamatsu, M; Nakashima, R; Nishizaki, T; Otsuki, Y; Sugita, N; Ueda, Y; Ueno, Y; Wakimoto, A; Yamada, T; Yamazaki, M; Yoshino, K | 1 |
| Aravantinos, G; Dimopoulos, MA; Economopoulos, T; Efstathiou, H; Farmakis, D; Fountzilas, G; Kalofonos, C; Pavlidis, N; Pectasides, D; Skarlos, D | 1 |
| Aoki, Y; Nishikawa, N; Tanaka, K; Yahata, T | 1 |
| Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Takeuchi, S; Tsuda, H; Udagawa, Y; Yaegashi, N | 2 |
| Coleman, RL; Crotzer, DR; Gershenson, DM; Levenback, CF; Sun, CC; Wolf, JK | 1 |
| Fukai, H; Matsumoto, H; Nakayama, Y; Ohta, Y; Sakamoto, H; Takami, M; Takimoto, T; Yamamoto, T | 1 |
| Ahmetović, B; Fatusić, Z; Iljazović, E; Ljuca, D | 1 |
| Aoki, D; Irimura, T; Susumu, N; Suzuki, N; Takeuchi, H; Tamada, Y | 1 |
| Maxwell, GL; McGuire, WP; Muggia, F; Rose, GS; Rose, PG; Rubin, SC; Sundborg, MJ; Tian, C; Winter, WE | 1 |
| Chu, CY; Hsiao, CH; Lee, HC | 1 |
| Dowdy, SC; Madarek, EO; Mariani, A; Mutch, DG; Podratz, KC; Powell, MA; Thomas, M; Wright, JD | 1 |
| Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Umezu, T | 1 |
| Brard, L; Charbonneau, N; Disilvestro, P; Dizon, DS; Granai, CO; Hughes, T; Legare, R; Lomme, M; Restivo, A; Weitzen, S | 1 |
| Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA | 1 |
| Ikeda, M; Kodama, S; Kudo, R; Nishiya, I; Noda, K; Nozawa, S; Taketani, Y; Tanaka, K; Terashima, Y; Yajima, A | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
| Chang, C; Imamura, K; Nishimura, H | 1 |
| Goldberg, JM; Hempling, RE; Piver, MS; Recio, FO | 1 |
| Aghajanian, C; Fennelly, D; McKenzie, M; Norton, L; O'Connor, C; O'Flaherty, C; Shapiro, F; Spriggs, D; Tong, W | 1 |
| Patsner, B | 1 |
| Asaoka, K; Ishitani, K; Iwasaki, K; Komuro, Y; Masumoto, N | 1 |
| Hayashi, K; Iida, T; Yonamine, K | 1 |
| Gorai, I; Hirahara, F; Kawata, N; Miyamoto, Y; Ohta, I; Shirotake, S; Yang, J; Zheng, JH | 1 |
| Fujiwara, K; Imajo, Y; Kohno, I; Maehata, K; Mikami, Y; Yoden, E | 1 |
| Ishioka, S; Kudo, R; Sagae, S | 1 |
| Arii, Y; Fujimura, H; Furuhashi, Y; Hattori, S; Ishikawa, H; Iwase, A; Kawai, M; Kikkawa, F; Kuzuya, K; Mizutani, S; Nakanishi, T; Nawa, A; Sakakibara, K; Sasayama, E; Suzuki, T | 1 |
| Konno, R | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
7 review(s) available for paclitaxel and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Long-term remission of clear cell carcinoma of the cervix after chemoradiation with 109 cycles of paclitaxel: a case report and literature review.
Topics: Adenocarcinoma, Clear Cell; Adult; Chemoradiotherapy; Female; Humans; Paclitaxel; Uterine Cervical Neoplasms | 2017 |
[Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cervix Uteri; Female; Fluorouracil; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Uterine Cervical Neoplasms | 2008 |
Emerging drugs for ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Primary clear cell carcinoma of a paratubal cyst: a case report with literature review.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Keratins; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Parovarian Cyst; Salpingectomy | 2011 |
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Resistance; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retreatment | 2002 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1996 |
[Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
22 trial(s) available for paclitaxel and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2020 |
Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2017 |
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Neurotoxicity Syndromes; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Physicians; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Survival Rate; Young Adult | 2017 |
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2014 |
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate | 2016 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2016 |
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Risk Factors; Survival Rate | 2010 |
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies | 2012 |
Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Lymph Nodes; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pelvis; Survival Rate | 2003 |
Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carcinoma, Endometrioid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radiography; Salvage Therapy; Survival Analysis; Treatment Outcome; Turkey | 2005 |
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors | 2008 |
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence | 2008 |
[A phase II study of BMS-181339 in patients with ovarian cancer. BMS-181339 Ovarian Cancer Study Group].
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Female; Fever; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1994 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1997 |
Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
105 other study(ies) available for paclitaxel and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Cisplatin; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Ovarian Cysts; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2021 |
Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Follow-Up Studies; Glutathione S-Transferase pi; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; X-ray Repair Cross Complementing Protein 1 | 2020 |
Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.
Topics: Adenocarcinoma, Clear Cell; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Paclitaxel; United States; Uterine Neoplasms | 2017 |
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Irinotecan; Ki-67 Antigen; M Phase Cell Cycle Checkpoints; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tissue Array Analysis | 2017 |
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Endometriosis; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Doxorubicin; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2013 |
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors | 2013 |
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Paclitaxel; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Detection of recurrence in a surveillance program for epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Treatment Outcome | 2014 |
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Suppressor Protein p53 | 2014 |
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cytotoxins; Dose-Response Relationship, Drug; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH | 2014 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Ovarian Neoplasms; Paclitaxel; Up-Regulation; Young Adult | 2014 |
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diagnostic Techniques, Surgical; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; Topotecan | 2014 |
Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Para-Aortic Bodies; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Pakistan; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2015 |
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden | 2017 |
Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cytokines; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2015 |
Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Progestins; Singapore; Sirolimus; Tamoxifen | 2015 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromosomes; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Expression; Humans; Irinotecan; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transcription Factors | 2016 |
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Multiprotein Complexes; Ovarian Neoplasms; Ovary; Paclitaxel; TOR Serine-Threonine Kinases | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Salpingectomy | 2016 |
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Endometriosis; Female; Fluorouracil; Humans; Hysterectomy; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Salpingectomy; Survival Rate | 2016 |
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors | 2016 |
[A Case of Primary Peritoneal Cancer Successfully Treated with Debulking Surgery and Postoperative Chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2016 |
A case of ovarian cancer associated with hypercalcemia.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Calcium; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Hypercalcemia; Hysterectomy; Lymph Node Excision; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Tomography, X-Ray Computed | 2008 |
Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cisplatin; Female; Humans; Immunohistochemistry; Microtubule-Associated Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stathmin; Tubulin | 2009 |
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Iridium Radioisotopes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2009 |
Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aged; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2009 |
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies | 2009 |
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Hypercholesterolemia; Hypertension; Immunohistochemistry; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant | 2009 |
Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Female; Gene Silencing; Glypicans; Humans; Mice; Molecular Sequence Data; Ovarian Neoplasms; Paclitaxel | 2010 |
Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Area Under Curve; Carboplatin; Female; Humans; Middle Aged; Nephritis, Interstitial; Ovarian Neoplasms; Paclitaxel; Renal Dialysis | 2009 |
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis | 2010 |
Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2009 |
[Analysis of prognostic factors of epithelial ovarian carcinoma].
Topics: Adenocarcinoma, Clear Cell; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Young Adult | 2010 |
Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drugs, Generic; Female; Humans; Mitosis; Ovarian Neoplasms; Paclitaxel | 2010 |
Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cisplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Analysis | 2010 |
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Japan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Failure | 2010 |
Neoadjuvant chemotherapy followed by radical vaginal trachelectomy and adjuvant chemotherapy for clear cell cancer of the cervix: a feasible approach and review.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cervix Uteri; Chemotherapy, Adjuvant; Female; Gynecologic Surgical Procedures; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1 | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
A case of chemotherapy-responsive paraneoplastic rubral tremor.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia; Autoantibodies; Brain Stem Neoplasms; Breast Neoplasms; Carboplatin; Electromyography; Enzyme-Linked Immunosorbent Assay; Female; Glasgow Coma Scale; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Nerve Tissue Proteins; Ovarian Neoplasms; Paclitaxel; Paraneoplastic Syndromes, Nervous System; Tomography, X-Ray Computed | 2011 |
Clinicopathological characteristics of ovarian carcinomas associated with endometriosis.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometriosis; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Salpingectomy | 2012 |
The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2012 |
The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Omentum; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2011 |
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cytokines; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Promoter Regions, Genetic; Reproducibility of Results; Tumor Suppressor Proteins | 2012 |
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Papillary; Carcinoma, Transitional Cell; Cell Proliferation; Cofilin 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Vitro Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Up-Regulation | 2013 |
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2002 |
Clear cell adenocarcinoma in a female urethral diverticulum.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Pelvic Exenteration; Radiography; Radiotherapy, Adjuvant; Urethral Neoplasms | 2003 |
[A case of ovarian cancer with Parkinson's disease treated by combined chemotherapy with paclitaxel and carboplatin followed by surgery].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Antiparkinson Agents; Area Under Curve; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Hysterectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Parkinson Disease | 2003 |
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53 | 2004 |
Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2004 |
Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Genes, p53; Humans; Microsatellite Repeats; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Survival Rate | 2006 |
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2006 |
Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Female; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Lysis Syndrome | 2006 |
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
[A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Hysterotomy; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction | 2007 |
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Treatment Outcome; Urokinase-Type Plasminogen Activator | 2007 |
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2007 |
Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Aged; Animals; Anoikis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Mice; Mice, Nude; Middle Aged; Mucin-1; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Prognosis; Sialic Acids; Survival Rate | 2007 |
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Medical Records; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2008 |
Carcinoma erysipeloides from ovarian clear-cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Female; Gynecologic Surgical Procedures; Humans; Lower Extremity; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms | 2007 |
Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Uterine Neoplasms | 2008 |
Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Tubulin | 2008 |
For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 1996 |
Ovarian epithelial carcinoma metastatic to the choroid of the eye: prolonged survival with radiation and taxol chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1998 |
[A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Remission Induction | 1999 |
Establishment and characterization of human ovarian clear cell adenocarcinoma cell line (SMOV-2), and its cytotoxity by anticancer agents.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cisplatin; Female; Genes, p53; Humans; Mice; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1999 |
Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
[A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2000 |
[Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2001 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |